Thelior Bio

Thelior Bio is a University of Oxford spin-out developing therapies for inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Its research focuses on restoring the intestinal epithelial barrier, addressing impaired tissue repair associated with chronic inflammation.

The company draws on molecular analysis of patient-derived tissue and spatial transcriptomics to identify therapeutic targets and develop treatments intended to promote mucosal healing. Its programmes are in early discovery and preclinical development.